COMPANY

Lucid Diagnostics

HQ: New York, NY source · luciddx.com ↗ · Mid-Atlantic

Location: New York, NY · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Barrett Esophagus Esophageal Adenocarcinoma Barretts Esophagus With Dysplasia Barrett's Esophagus Without Dysplasia Esophagus Adenocarcinoma EsoGuard EsoCheck® EsoGuard (lab assay) EsoGuard result

$76.3MRaised (2 yrs)5Trials (company is sponsor)

Timeline

Apr 24, 2026 Raise Follow-on offering: $18M (total, as published), announced Apr 24, 2026. Source: SEC filing. source ↗
Sep 11, 2025 Raise Follow-on offering: $26.9M (total, as published), announced Sep 11, 2025. Source: SEC filing. source ↗
Apr 11, 2025 Raise Follow-on offering: $16.1M (total, as published), announced Apr 11, 2025. Source: SEC filing. source ↗
Mar 5, 2025 Raise Follow-on offering — Registered direct: $15.3M (total, as published), announced Mar 5, 2025. Source: SEC filing. source ↗
Apr 12, 2023 Trial start Not phased (device or behavioral study): Clinical Utility of a Non Endoscopic Device EsoCheck and Biomarker EsoGuard as Alternative to Endoscopy for Screening for Barrett's Esophagus in At Risk Population source ↗
Apr 11, 2023 Trial start —: Lucid Registry Study source ↗
Feb 23, 2023 Trial start Not phased (device or behavioral study): CLUE: CLinical Utility Study of EsoGuard source ↗
Jun 18, 2020 Trial start Not phased (device or behavioral study): Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC source ↗
Feb 28, 2020 Trial start Not phased (device or behavioral study): Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE source ↗

Upcoming milestones

Jun 1, 2027 (ESTIMATED) · Not phased · Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC · NCT04295811
Dec 31, 2027 (ESTIMATED) · · Lucid Registry Study · NCT05965999

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $76.3M. Last 2 years.

Apr 24, 2026 Follow-on offering: $18M (total, as published), announced Apr 24, 2026. Source: SEC filing. source ↗
Sep 11, 2025 Follow-on offering: $26.9M (total, as published), announced Sep 11, 2025. Source: SEC filing. source ↗
Apr 11, 2025 Follow-on offering: $16.1M (total, as published), announced Apr 11, 2025. Source: SEC filing. source ↗
Mar 5, 2025 Follow-on offering — Registered direct: $15.3M (total, as published), announced Mar 5, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT05965999	Lucid Registry Study	Not listed	Recruiting	Apr 11, 2023	Dec 31, 2027 (estimated)
NCT04295811	Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC	Not phased (device or behavioral study)	Active, not recruiting	Jun 18, 2020	Jun 1, 2027 (estimated)
NCT05778851	Clinical Utility of a Non Endoscopic Device EsoCheck and Biomarker EsoGuard as Alternative to Endoscopy for Screening for Barrett's Esophagus in At Risk Population	Not phased (device or behavioral study)	Completed	Apr 12, 2023	Jul 31, 2024 (actual)
NCT06030180	CLUE: CLinical Utility Study of EsoGuard	Not phased (device or behavioral study)	Completed	Feb 23, 2023	Dec 13, 2024 (actual)
NCT04293458	Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE	Not phased (device or behavioral study)	Completed	Feb 28, 2020	Aug 22, 2022 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2024-12-06 Raise Private raise (SEC Form D): $21.9M sold; issuer “Lucid Diagnostics Inc.”. Verified from the SEC filing. SEC filing ↗